Contents & References of Investigating the increase of simvastatin drug solubility using solid dispersion method
List:
Title
Page Title
Persian Summary. 1
Chapter One: Generalities
1-1 - Statement of the issue and the importance of the issue. 3
1-2-Objectives: 4
Chapter Two: Reviewing the texts and studies of others
Part One: General information about poorly soluble drugs and methods of increasing solubility
2-1-1-Dissolution and absorption of drugs. 7
2-1-2- Liquidation. 9
2-1-3- Dissolution theories. 9
2-1-4- dissolution speed. 10
2-1-5- Classification of drugs from the point of view of solubility and permeability. 11
2-1-6- methods of increasing solubility. 13
2-1-6-1- Use of solvents 13
2-1-6-2- Use of surfactants 14
2-1-6-3- Use of cyclodextrins: 14
2-1-6-4- pH adjustment: 15
2-1-6-8-4- Disadvantages of dispersions solid. 26
2-1-6-8-5- The future of solid dispersions. 27
2-1-6-8-6- Evaluating the efficiency of solid dispersions in in vitro conditions. 27
2-1-6-8-7- Choosing the right carrier for solid dispersion. 28
2-1-7- Materials used. 28
2-1-7-1- sodium lauryl sulfate. 28
2-1-7-2-Polyethylene Glycol (PEG): 30
2-1-7-3-Ethanol: 33
2-1-7-4-Polyvinyl Pyrrolidine ((PVP: 33
2-1-7-5-Hydroxypropyl Methyl Cellulose (HPMC)) 35
2-1-7-6- Glyceryl behenate: 37
2-1-7-7- Avicel 102pH (microcrystalline cellulose): 38
2-1-7-8-: Gelucire 43/01. 39
2-1-7-9- Polysorbates: 40
2-1-7-magnesium stearate: 41 2-1-7-mannitol
2-2-Mechanism of action: 47
2-2-3- Other cardioprotective effects of statins: 48
2-2-4- Statins and endothelial function: 48
2-2-5- Statins and plaque stability: 48
2-2-6- Other effects of statins: 49
2-2-7- The toxicity of statins: 2-2-8- Simvastatin. 51- Physicochemical properties of simvastatin. 52- 2-8-3- Pharmacokinetics
2-2-8-4- side effects. 53
2-2-8-5- Cases and dosage. 54
2-2-8-6- Precautions and contraindications. 54
2-2-8-7- Medicinal forms: 54
Part three: review of some articles and studies of others in this field
2-3-1 review of some studies of others. 56
Chapter Three: Materials and Methods
3-1-Introduction. 60
3-1- Devices: 61
3-2- Materials. 62
3-3- Pre-formulation studies. 62
3-4- Manufacturing methods of simvastatin solid dispersion formulations. 65
3-4-1- Construction of simvastatin solid dispersion systems of group A formulations. 65
3-4-2- Construction of simvastatin solid dispersion systems of group B formulations. 66
3-4-3- Construction of solid dispersion systems of simvastatin group C formulations. 67
3-4-4- Construction of solid dispersion systems of simvastatin group D formulation. 67
3-4-5- Construction of solid dispersion systems of simvastatin group E formulation. 68
3-4-6- Fabrication of solid dispersion systems of simvastatin group F formulation. 69
3-5-Control tests of prepared solid dispersion formulations 70
3-5-1-Saturation solubility. 70
3-5-2- Statistical study of saturated solubility in order to select superior formulations. 70
3-6- Additional tests on selected formulations. 70
3-6-1- Determining the amount of the active ingredient of the tablet prepared from the selected formulations. 71
3-6-2- Dissolution speed test on selected formulations. 71
3-6-3- Examining the similarity between the selected formulations. 71
3-6-4- Flowability study of selected formulations. 71
3-6-5- Determining the saturation solubility of physical mixing of superior formulations. 72
3-6-6- Flowability study of physical mixing of selected formulations. 72
3-6-7- Examining the FTIR spectra of superior formulations. 72
3-6-8-72
3-6-8- Examining the diagrams obtained from DSC of superior formulation. 73
Chapter Four: Results
4-1- The results of pre-formulation studies. 75
4-2- The results of control tests of prepared solid dispersion formulations 80
4-2-1. Results from saturation solubility. 80
4-2-2. Investigation of statistical studies of saturated solubility in order to select superior formulations. 85
4-3- Additional tests on selected formulations. 93
4-3-1- Determining the amount of the active ingredient of the tablet prepared from the selected formulations. 93
4-3-2- Dissolution speed test on selected formulations. 93
4-3-3- Examining the similarity between selected formulations. 102
4-3-4- Results of study of flowability and compressibility of selected formulations. 102
4-3-5- Results of saturation solubility of physical mixing of selected formulations. 103
4-3-6- The results of the study of flowability and compressibility of physical mixing of selected formulations. 103
4-3-7- The spectra obtained from FTIR spectroscopy of the superior formulation (B10) 104
4-3-8- The diagrams obtained from DSC of the superior formulation (B10) 106
Chapter five: Discussion and conclusion
5-1- Introduction. 110
5-2- Examining the results of statistical studies on the saturation solubility of the prepared formulations in order to select the selected formulations. 110
5-3- Examining additional tests on selected formulations. 116
5-3-1- Examining the results of determining the amount of the active ingredient in the tablets prepared from the selected formulations. 116
5-3-2- Examining the results of the dissolution rate test of tablets prepared from selected formulations. 116
5-3-3- Examining the results of flowability and compressibility studies of selected formulations. 117
5-3-4- Examining the saturation solubility results of physical mixing of selected formulations. 118
5-3-5- Examining the results of flowability and compressibility studies of physical mixing of selected formulations. 118
5-4- Choosing the best formula and additional studies on it. 119
5-4- 1- Analysis of spectra obtained from FTIR spectroscopy of the superior formulation. 119
5-4-2- Analysis of diagrams obtained from DSC of the superior formulation. 119
5-8- General conclusion. 120
5-9- Suggestions. 121
English summary. 122
Resources. 124
Source:
1- Ohahia T., Kitamura S., Kitagava M., Terada K. Dissolution mechanism of poorly water soluble drug from extended release solid dispersion system with ethylecellulose and hydroxypropylmethyl cellulose. Int. J. Pharm. 2005; 302:95-102
2- Leuner C., Dressman JB. Improving drug solubility for oral delivery using solid dispersions. Eure. J. pharm. Sci. 2000; 50:47-60
3- Amidon GL., Lenneras H., shah VP., Crison JR. A theoretical basis for a biopharmaceutical drug classification, the correlation for in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1955; 12: 413-420
4- Chiou WL., Riegelan S. Pharmaceutical applications of solid dispersion systems. J. pharm. Sci. 1971; 60: 1281-1302
5-Serajuddin A.T.M Solid dispersion of poor water-soluble drugs: early promises, subsequent problems and recent breakthroughs. J, pharm. Sci. 1999;88:1058-1066
6-Motsumoto T., Zografi G. Physical properties of solid molecule dispersions of imdomethacin with PVP VA in relation to indomethacin crystallization. Pharm. Res. 1999; 16:1722-1728
7-Van den Mooter G, [et al]. Physical stabilization of amorphous ketoconazole in solid dispersion with polyvinylpyrrolidone k25. Eur. J. pharm. Sci. 2001; 12:261-269
8- Isoherranen N., Kunze K.L., Aleen K.E., Nelson W.L., Tunmel K.E. Role of Itraconazol metabolites in CYP3A4 inhibition. Drug metabolite disposition. 2004; 32:1121-1131
9- Allen L.V., Popovich NG., Ancel H.C. Ansel's pharmaceutical dosage forms and drug delivery system. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. Pp 148,166-7
10- Rafiei Tehrani, Morteza. pill making Tehran: University of Tehran; 1377. pp. 21-9, 416-415
11- The united state pharmacopeia. 31st rev. Rockville; 2008. Vol 1. P268-270
12- Rafiei Tehrani, Morteza. pill making